Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Bausch Health Companies Inc    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC

(BHC)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Bausch Health : Up Over 12%, on Pace for Largest Percent Increase Since Nov 2017 -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/12/2018 | 11:45am EDT

Bausch Health Companies Inc. (BHC) is currently at $23.25, up $2.58 or 12.48%.

-- Would be highest close since Aug. 30, 2018, when it closed at $23.60

-- On pace for largest percent increase since Nov. 7, 2017, when it rose 17.11%

-- Earlier Wednesday, Bausch Health along with its wholly owned subsidiary, Salix Pharmaceuticals, said it has reached an agreement in a patent dispute over 550 mg tablets of Xifaxan

-- Up 11.89% year-to-date

-- Up 64.78% from 52 weeks ago (Sept. 13, 2017), when it closed at $14.11

-- Up 110.22% from its 52-week closing low of $11.06 on Nov. 2, 2017

-- Traded as high as $24.10; highest intraday level since Aug. 8, 2018, when it hit $24.30

-- Up 16.59% at today's intraday high; largest intraday percent increase since May 8, 2018, when it rose as much as 17.18%

All data as of 11:16:34 AM

Source: Dow Jones Market Data, FactSet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAUSCH HEALTH COMPANIES IN
07/18BAUSCH HEALTH COMPANIES INC : . - Court Upholds the Validity and Determined Acta..
AQ
07/17BAUSCH HEALTH : Court Upholds The Validity And Determined Actavis' Infringement ..
PR
07/17PROGENICS PHARMACEUTICALS : Court Upholds The Validity And Determined Actavis' I..
AQ
07/12ETON PHARMACEUTICALS : Down Nearly 17% As FDA Doesn't Approve EM-100
DJ
07/09BAUSCH HEALTH : + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamin..
PR
07/08BAUSCH HEALTH COMPANIES INC : . Will Release Second-Quarter 2019 Financial Resul..
AQ
06/26BAUSCH HEALTH : Announces U.S. Launch of DUOBRII Lotion 0.01%/0.045% for Plaque ..
AQ
06/25AbbVie, Lennar and FedEx fall while Bausch Health rises
AQ
06/25BAUSCH HEALTH : To Reduce Debt By Additional $100 Million Using Cash Generated F..
AQ
06/25BAUSCH HEALTH : Announces U.S. Launch of DUOBRII™ (halobetasol propionate ..
AQ
More news
Financials (USD)
Sales 2019 8 487 M
EBIT 2019 3 242 M
Net income 2019 -603 M
Debt 2019 22 757 M
Yield 2019 -
P/E ratio 2019 -10,5x
P/E ratio 2020 -9,08x
EV / Sales2019 3,42x
EV / Sales2020 3,13x
Capitalization 6 231 M
Chart BAUSCH HEALTH COMPANIES INC
Duration : Period :
Bausch Health Companies Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES IN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price
Last Close Price 23,06  $
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Jerzy Janeczko Head-Information Technology
Calvin W. Roberts Chief Medical Officer & Senior Vice President
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC19.13%8 129
JOHNSON & JOHNSON2.18%350 653
PFIZER-2.08%239 061
ROCHE HOLDING LTD.11.42%234 924
ROCHE HOLDING13.37%234 924
NOVARTIS24.46%217 699